A Systematic Review of Nonpharmacologic Interventions for Treatment-Related Symptoms in Women With Ovarian Cancer

Abstract

Nonpharmacologic interventions for treatment-related symptoms were complex, with an average of 4.4 components. Intervention delivery, setting, and exposure varied widely across studies. Only three studies contained details sufficient to replicate the intervention. Lack of clarity in intervention reporting may explain perceptions of clinically inefficacious symptom management in this context. Greater attention to reporting would facilitate better translation of interventions into practice and when addressing complex cancer symptom clusters.

Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer

“…Women with ovarian cancer demonstrated continued symptoms of depression and anxiety for cancer survivors who had undergone chemotherapy treatment, according to a meta-analysis of prevalence rates ( 4 ). Ineffective or prolonged management of treatment could contribute to worsening of symptoms, treatment noncompliance and even reduced health-related quality of life ( 5 ).…”

Can supervised group‐based multimodal exercise improve health‐related quality of life in women with ovarian cancer undergoing chemotherapy?

“…Non‐pharmacological interventions such as nurse‐led telephone interventions, pain‐reducing or psycho‐educational programmes to address reductions in HRQoL have shown no convincing effect in women with ovarian cancer (Cook et al, 2015; Davis & Carpenter, 2015; Kalter et al, 2018). Likewise and despite the increased attention given to exercise oncology (McTiernan et al, 2019), only a few small‐scaled intervention studies ( n = 17–30), are available examining HRQoL in women with ovarian cancer undergoing chemotherapy, which is why the results must be applied with caution (Mizrahi et al, 2015; Moonsammy et al, 2013; Newton et al, 2011; von Gruenigen et al, 2011).…”

Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin‑mediated PI3K/AKT signaling pathway

“…Using a meta-analysis of prevalence rates, it was identified that females with ovarian cancer who had undergone chemotherapy treatment demonstrated continued symptoms of depression and anxiety (4). Ineffective or prolonged management of treatments may contribute to the worsening of symptoms, treatment noncompliance and even a decrease in health-associated quality of life (5). Although previous studies have proposed certain improvements in early diagnosis and anticancer therapies for ovarian carcinoma (6)(7)(8)(9), metastasis remains the major challenge in the treatment of ovarian carcinoma.…”